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Abstract 
Background: The extended-spectrum β-lactamase (ESBL) producing bacteria are present as the serious public health 
problems due to their resistance to large number of antibiotics. The main aims of this study were to determine the 
prevalence and antibiotic resistance patterns of bacteria producing extended-spectrum β-lactamases (ESBLs) and to 
find the suitable cephalosporin/clavulanate combination for phenotypic confirmation of ESBL production.
Methods: During the study period from April 2013 to November 2013, a total of 1003 urine samples from the 
patients visiting National Public Health Laboratory, Kathmandu, Nepal were collected and processed. The isolates 
were identified with the help of colony characteristics, gram stain and conventional biochemical tests. Antimicrobial 
susceptibility testing was performed by Kirby Bauer disc diffusion method. ESBL production screening was done by 
using ceftriaxone, while ESBL production confirmation was done by using three different 3rd generation cephalo-
sporin/clavulanate combinations.
Results: Of the 138 isolates, Escherichia coli was the most predominant with 88 (63.8 %) isolates. Among the antibiot-
ics tested for gram negative bacteria, highest susceptibility was seen toward imipenem followed by amikacin. Of the 
total isolates, 68 (49.3 %) were suspected as ESBL producers. Of these, 44 (64.7 %) were phenotypically confirmed to 
be ESBL producers. The majority of ESBL producers were E. coli with 34 (72.3 %) isolates. Of the three different 3rd gen-
eration cephalosporin/clavulanate combinations used, ceftazidime/clavulanate combination was found to be most 
effective for phenotypic confirmation of ESBL producers and was statistically highly significant (P < 0.01).
Conclusion: Based on the findings of our study, we recommend to use ceftazidime/clavulanate combination for 
phenotypic confirmation of ESBL producers. Routine ESBL testing for uropathogens along with conventional antibio-
gram would be useful for proper early management of all the cases of urinary tract infections.
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Background
Urinary tract infection (UTI) is one of the most common 
bacterial infections in humans both in the community 
and hospital setting, and are associated with significant 
morbidity and mortality as well as high economic bur-
den on society [1]. The disease may be asymptomatic, 
but if symptoms develop they include cloudy or bloody 
urine, low-grade fever, back discomfort, fatigue, nausea 
and vomiting [2]. Most common causative agents of UTI 
are bacteria of enteric origin and among them Escheri-
chia coli is the most frequent uropathogen [3]. Antibiotic 
resistance in bacteria is increasing worldwide in both out 
patients and hospitalized patients. It varies according to 
geographic location and the haphazard use of antibiot-
ics is playing a significant role in the emergence of the 
drug  resistant bacteria [4, 5]. The β-lactamases are the 
major defense of gram negative bacteria against β-lactam 
antibiotics. Extended-spectrum β-lactamase (ESBL) pro-
ducing organisms have been increasingly detected world-
wide with their varying prevalence in different settings 
and the extent of the problem is under-recognized due to 
unawareness and poor laboratory detection and report-
ing at many centers [6]. Considering, the rapid rise in 
ESBL producing organisms and the lack of accurate fig-
ures about the prevalence and the resistance patterns of 
clinically relevant bacteria producing ESBL in Nepalese 
population, we conducted this study. Further this study 
will be helpful for the laboratory personnel to choose 
most effective cephalosporin/clavulanate combination 
for phenotypic confirmation of ESBL production.
We processed urine samples of patients suspected of 
UTI to determine prevalence and the antibiotic suscep-
tibility patterns of clinically relevant bacteria producing 
extended spectrum β-lactamases and to find the suitable 
cephalosporin/clavulanate combination for phenotypic 
confirmation of ESBL producing bacteria.
Methods
The study was conducted at National Public Health Lab-
oratory, Teku, Kathmandu, Nepal from April 2013 to 
November 2013. During this period, a total of 1003 urine 
samples from patients suspected of UTI were collected 
and processed by using standard laboratory methods.
Sample collection and transportation
The patients were given a clean, wide mouth, dry and 
sterile leak proof container and requested for 5–10  ml 
mid-stream urine sample. Before providing the container, 
each patient was instructed properly for the collection 
of sample. The container was then labelled properly and 
immediately delivered to the laboratory with the request 
form for further processing. The quality of the sample 
was evaluated before processing in terms of proper label-
ling, visible signs of contamination, improper screwing 
of cap etc. The improper sample was rejected and the 
patient was requested to submit next sample.
Culture of specimen
Culture of each urine sample was done on Cystine Lac-
tose Electrolyte Deficient agar plate. An inoculating loop 
of standard dimension was used to take up fixed and a 
known volume (0.001 ml) of mixed uncentrifuged urine 
for inoculation. After inoculation the plates were incu-
bated aerobically at 37 °C for 24 h and were observed for 
significant growth (105 cfu/ml).
Identification of the isolates
Isolated bacteria were identified by using standard 
microbiological tools and techniques as described in the 
Bergey’s manual of systematic bacteriology which involve 
morphological appearance of the colonies, staining reac-
tion and biochemical properties. Each of the organism 
was isolated in pure form before performing biochemi-
cal tests. The biochemical tests used for the identification 
included catalase test, oxidase test, sulfide indole and 
motility test, methyl red test, Voges Proskauer test, cit-
rate utilization test, oxidation fermentation test and tri-
ple sugar iron test.
Antibiotic susceptibility testing
The antimicrobial susceptibility testing was done by 
modified Kirby-Bauer disk diffusion method as recom-
mended by Clinical and Laboratory Standards Institute 
(CLSI) using Mueller–Hinton agar [7].
Screening and confirmation of ESBL producing isolates
Bacterial isolates were first tested with ceftriaxone 
(30  µg) as per the CLSI screening criteria. The isolates 
were suspected to be ESBL producers, if zone of inhibi-
tion was  ≤25  mm. The suspected ESBL producing iso-
lates were tested for confirmation for ESBL production 
by combined disc method, using cefpodoxime (10  µg) 
and cefpodoxime (10 µg) + clavulanate (1 µg), cefotaxime 
(30 µg) and cefotaxime (30 µg) + clavulanate (10 µg) and 
ceftazidime (30  µg) and ceftazidime (30  µg)  +  clavula-
nate (10 µg). An increase in zone diameter of ≥5 mm in 
the presence of clavulanate from any or all of the set was 
confirmed as ESBL production. The antibiotic discs used 
in the study were supplied by Hi-media laboratories pvt. 
ltd., India. As controls, E. coli ATCC 25922 (ESBL nega-
tive) and  Klebsiella pneumoniae  ATCC 700603 (ESBL 
positive) were used.
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Data analysis
SPSS version 19.0 was used for statistical analysis. Chi-
square test was applied and P < 0.01 was considered sta-
tistically significant.
Results
A total of 1003 urine samples were processed for culture, 
of which 611 (60.9 %) were from male patients and 392 
(39.1 %) were from  female patients. Of the 611 samples 
from male, 63 (10.3 %) showed significant growth. Simi-
larly, of the 392 samples from female, 75 (19.1 %) showed 
significant growth.
Distribution of urinary isolates
Total of 138 bacteria belonging to 13 different spe-
cies were isolated (Table  1). Among the isolates gram 
negative bacteria were found predominant constituting 
134   (97.10 %) out of 138. Of all the isolates, E. coli was 
the most frequently isolated species (63.8 %) followed by 
Pseudomonas aeruginosa (8.7 %). The least common iso-
lates were Edwardsiella spp., Providencia spp., and Serra-
tia spp. Similarly gram positive bacteria constitute 2.9 % 
of the total  isolates and Staphylococcus aureus was the 
only gram positive bacterium isolated.
Among the 138 growth positive samples, 63 (45.7  %) 
were from  males and 75 (54.3  %) were from  females. 
Among the different isolates, E. coli was the most pre-
dominant bacteria both in male 38 (43.2  %) and female 
50 (56.8 %).
Antibiotic susceptibility patterns of gram negative isolates
Out of 13 antibiotics tested for gram negative isolates, 
7 different antibiotics (belonging to 5 different classes) 
were used as first line drugs and other six antibiot-
ics were used as second line drugs. Among the first line 
drugs used, highest rate of susceptibility was shown to 
nitrofurantoin (61.9  %) and which is statistically signifi-
cant (P < 0.01). Among the second line drugs used, high-
est rate of susceptibility was shown toward imipenem 
(96.4 %) followed by amikacin (91.1 %) and piperacillin/
tazobactam (69.6 %). Ampicillin was found as the drug to 
which most strains were resistant with only 24.6 % of iso-
lates being susceptible (Table 2).
ESBL production among various isolates
Of the 68 suspected ESBL positive  isolates, 44 (64.7  %) 
were ESBL positive whereas 24 (35.3  %) were ESBL 
negative on confirmation (Table 3). Among the 44 ESBL 
positive isolates, the majority consist of E. coli (77.27 %). 
Of the total primary screened E. coli 72.3 % were ESBL 
positive.
Confirmation of ESBL production using 3 different 
cephalosporins and respective clavulanic acid combination 
disks
Among the 68 suspected ESBL positive isolates that were 
subjected to ESBL confirmation test using three differ-
ent combination disks, the ceftazidime/ceftazidime+ 
clavulanate detected 44 ESBL positive isolates whereas 
Table 1 Gender wise distribution of urinary isolates
Organisms isolated Male Female Total
No. of isolates % No. of isolates % No. of isolates %
Gram negative bacteria
Acinetobacter spp. 5 83.3 1 16.7 6 4.3
Citrobacter koseri 3 50 3 50 6 4.3
Citrobacter freundii 0 0 4 100 4 2.9
E. coli 38 43.2 50 56.8 88 63.8
Edwardsiella spp. 1 100 0 0 1 0.7
Enterobacter spp. 1 50 1 50 2 1.4
Kl. pneumoniae 2 25 6 75 8 5.8
Morganella morganii 1 50 1 50 2 1.4
Proteus spp. 2 66.7 1 33.3 3 2.2
Providencia spp. 1 100 0 0 1 0.7
Pseudomonas aeruginosa 8 66.7 4 33.3 12 8.7
Serratia spp. 0 0 1 100 1 0.7
Gram positive bacteria
S. aureus 1 25 3 75 4 2.9
Total 63 45.7 75 54.3 138 100
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cefpodoxime/cefpodoxime+ clavulanate and cefotaxime/
cefotaxime+ clavulanate detected 38 and 36 ESBL posi-
tive isolates respectively (Table  4). Ceftazidime/clavu-
lanate was found relatively suitable in detection of ESBL 
positive isolates and was statistically significant (P < 0.01).
Discussion
Similar to our study the studies carried out by Tankhi-
wale et al., Begum et al. and Baral et al. showed a low per-
centage of growth positivity [8–10]. The reason behind 
the low growth rate observed in this study might be due 
to the prior use of antibiotics, infection due to slow grow-
ing organisms or due to those organisms that were not 
able to grow on the routine media we used. Our findings 
were in accordance with the findings of Awasthi et  al. 
[11] who found 95.92 % of the urinary isolates to be gram 
negative bacteria and 4.08  % of the isolates to be gram 
positive bacteria. Higher prevalence of E. coli seen in our 
study also resembled the results of the studies done by 
other researchers [10, 12–14].
Our finding regarding the susceptibility of the gram 
negative bacteria toward  nitrofurantoin resembled the 
findings reported by Tankhiwale et  al. and Baral et  al. 
[8, 10]. Nitrofurantoin should be considered as drug of 
choice for acute, uncomplicated UTI due to its specific-
ity toward urinary tract and low level of in  vitro resist-
ance shown by the bacteria [15]. Nitrofurantoin is not 
Table 2 Antibiotic susceptibility patterns of gram negative isolates
Antibiotics used Susceptible Intermediate Resistant Total
No % No % No %
First line drugs
Ampicillin 33 24.6 0 0 101 75.4 134
Amoxycillin + clavulanic acid 49 36.6 2 1.5 83 61.9 134
Ciprofloxacin 57 42.5 1 0.7 76 56.7 134
Cotrimoxazole 51 38.1 0 0 83 61.9 134
Ceftriaxone 65 48.5 2 1.5 67 50 134
Nitrofurantoin 83 61.9 7 5.2 44 32.8 134
Norfloxacin 55 41 0 0 79 59 134
Second line drugs
Amikacin 51 91.1 1 1.8 4 7.1 56
Cefoxitin 19 33.9 5 8.9 32 57.1 56
Ceftazidime 15 25.9 1 1.7 42 72.4 58
Gentamicin 26 46.4 2 3.6 28 50 56
Imipenem 54 96.4 0 0 2 3.6 56
Piperacillin/tazobactam 39 69.6 3 5.4 14 25 56
Table 3 ESBL production by various isolates





Positive % Negative %
Acinetobacter spp. 3 1 33.3 2 66.7
Citrobacter koseri 1 1 100 0 0
Citrobacter freundii 1 1 100 0 0
E. coli 47 34 72.3 13 27.7
Edwardsiella spp. 1 1 100 0 0
Enterobacter spp. 2 2 100 0 0
Kl. pneumoniae 5 2 40 3 60
Ps. aeruginosa 8 2 25 6 75
Total 68 44 64.7 24 35.3
Table 4 ESBL production detected by 3 different combination disks
CPD cefpodoxime, CAZ ceftazidime, CTX cefotaxime, CV clavulanate
Combination disks 
used










CPD, CPD+CV Increase in zone size of ≥5 mm 
with ≥1 combination disks
68 38 44 24
CTX, CTX+CV 36
CAZ, CAZ+CV 44
Page 5 of 5Bhandari et al. BMC Res Notes  (2016) 9:390 
generally prescribed in UTI caused by Proteus spp. as 
this urease producing organism render urine alkaline 
and thus decreasing the potency of the drug in vivo [16]. 
Among the antibiotics evaluated secondarily, highest 
numbers of the gram negative isolates were found to be 
susceptible to imipenem followed by amikacin. Higher 
resistance to penicillins seen in our study might be due 
to the production of penicillin destroying enzymes 
(β-lactamases) by the bacteria.
In our study, the rate of ESBL production among the 
uropathogens was similar to the rates of ESBL produc-
tion reported by other studies [2, 10]. In our study three 
different cephalosporins combination with clavulanic 
acid were used for confirmation of ESBL production 
and maximum ESBL production was detected by CAZ/
CAZ+CV combination which correlated with another 
study [17].
Limitation of the study
Since this study was conducted in the low income coun-
try, where the availability of the advanced laboratory is 
not easy, we could not use molecular techniques to con-
firm our findings.
Conclusion
Among the three different combination disks, CAZ/
CAZ+CV was found to be the best combination in con-
firmation of ESBL production. Routine ESBL production 
testing for uropathogens along with conventional anti-
biogram would be useful for early proper management of 
all cases of UTIs.
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